Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
461studies shown
Showing 217-228 of 461
Drug study icon
CompletedNCT02713282

Transition to the Paliperidone Palmitate 3-Month Formulation for schizophrenia

This study is completed in France, in the United Kingdom, in Croatia, .... It is testing Transition to the Paliperidone Palmitate 3-Month Formulation for schizophrenia.

In France
SchizophreniaDrugA study involving a medication or substance.From 18 Years to 50 Years
Countries
France, United Kingdom, Croatia, ...
Sponsor
Janssen-Cilag Ltd.
Condition
Schizophrenia
Drug study icon
CompletedNCT00490971

Effectiveness of Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Bipolarity

This study is completed in the United States, in France, in Bulgaria, .... It is testing Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo for Bipolarity.

In France
BipolarityDrugFrom 18 Years to 65 Years
Countries
United States, France, Bulgaria, ...
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Condition
Bipolarity
Drug study icon
Enrolling By InvitationNCT06194799

ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

This study is enrolling by invitation. It focuses on schizophrenia and currently lists participation information in Brazil, Bulgaria, Chile, Czech Republic, France, Italy, Mexico, Serbia, South Korea, Spain, Taiwan, and the United States.

In France
SchizophreniaDrugFrom 55 Years to 95 Years
Countries
United States, France, Brazil, ...
Sponsor
ACADIA Pharmaceuticals Inc.
Condition
Schizophrenia